GlassScriptPhysician profile
Yu Hwong
NPI 1306899208
$2,793.21
in general payments reported to CMS, 2019-2025
13 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $917 · 2020: $275 · 2021: $423 · 2022: $236 · 2023: $525 · 2024: $235 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $942.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $941.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $667.97 | 2019-2024 | Xtandi, Myrbetriq |
| Janssen Biotech, INC. | $578.11 | 2019-2024 | Erleada, Akeega |
| Sumitomo Pharma America, INC. | $434.83 | 2023-2025 | Gemtesa, Orgovyx |
| Pfizer INC. | $335.77 | 2019-2024 | |
| Urovant Sciences INC | $298.75 | 2021-2022 | |
| Boston Scientific Corporation | $110.06 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $81.20 | 2019-2023 | |
| Ferring Pharmaceuticals INC. | $78.95 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $66.00 | 2024-2025 | Lynparza |
| Progenics Pharmaceuticals, INC. | $56.52 | 2022-2025 | |
| Amgen INC. | $32.47 | 2023 | Xgeva |
| Dendreon Pharmaceuticals LLC | $30.71 | 2019 | |
| Accord Healthcare, INC. | $21.87 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yu Hwong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.